Imagine a single medical intervention that keeps cholesterol levels stable for decades, removing the need for daily pills. Advances in gene editing are moving this concept closer to reality. However, scientists caution that the same technology capable of revolutionizing medicine also introduces complex questions regarding safety, permanent genetic alterations, and potential unintended consequences.
Gene therapy is already established in treating certain severe illnesses. These treatments can introduce functional gene copies, silence harmful genetic activity, or modify DNA directly. Unlike conventional medications that require repeated administration, some genetic treatments are designed to function after a single dose. More than 6,000 rare genetic disorders have been identified, with gene therapies achieving notable successes against conditions like spinal muscular atrophy and sickle cell disease.
Challenges of Permanent Genetic Changes
Researchers are now exploring whether similar approaches can manage widespread health issues, including high cholesterol, heart disease, obesity, and diabetes. This expansion raises a fundamental question: just because scientists can permanently alter genetic activity, should they?
In a perspective published in JAMA Internal Medicine, cardiologists Eric D. Smith and Venkatesh L. Murthy from the University of Michigan Health Frankel Cardiovascular Center outline how doctors and researchers should weigh the potential benefits of genomic therapies against their risks. They explain why these treatments are promising, how they differ from conventional medicines, and what must happen before they can be safely offered to millions.
One of the most appealing features of gene therapy is the possibility of achieving lasting results without repeated treatments. Traditional medicines generally work only as long as patients continue taking them. Genomic therapies operate differently because they act on genetic material itself. They may provide a healthy version of a gene, suppress a gene responsible for harmful effects, or modify a specific DNA sequence.
However, receiving a treatment only once does not necessarily mean its effects will last a lifetime. Smith explains that many gene therapies use modified viruses to carry genetic instructions into cells. The immune system can recognize these delivery vehicles and develop a response against them. As a result, administering the same treatment again may be difficult or impossible, even if its benefits begin to fade.
Another important distinction concerns which cells are changed. Current gene therapies generally target somatic cells, which are the body’s cells other than those involved in reproduction. Unlike germline editing, these treatments are not intended to create genetic changes that can be inherited by future generations.
Safety and Cost Barriers
For people living with rare, devastating genetic conditions, the benefits of gene therapy may clearly outweigh the potential dangers. Some patients have few effective treatment options, making even an experimental intervention worth considering. The situation becomes considerably more complicated when the same technology is used against common diseases.
Conditions such as high cholesterol, heart disease, obesity, and diabetes already have established treatments. Many of these medications can be adjusted as a patient’s condition changes or discontinued if troublesome side effects develop. A permanent genetic intervention may not offer that flexibility. Murthy also points to a major concern involving the number of people who might eventually receive these treatments. A serious side effect that occurs only rarely could still harm a substantial number of patients if a therapy is administered to millions.
To help determine when genomic therapy is appropriate, Smith and Murthy propose evaluating five essential factors. Clinical trials typically involve relatively small groups of patients who are monitored for limited periods. Although these studies can identify many important safety concerns, they may miss extremely rare complications or problems that take years to develop. Some adverse effects might only become apparent after a treatment has reached a much larger population.
Smith argues that long-term monitoring cannot be treated as an afterthought. It needs to be an essential part of how gene therapies are introduced into medical practice. Patient registries, which collect information about people receiving particular treatments, have already shown how valuable extended follow-up can be. However, therapies that could eventually reach millions of patients will require monitoring systems capable of operating on a much larger scale.
Safety is not the only barrier to bringing gene editing into mainstream healthcare. Cost could also determine whether these treatments become widely available. Some existing gene therapies have list prices above $1 million for a single patient, and several cost substantially more. Such prices may be considered justifiable for certain rare, life-threatening conditions, particularly when treatment options are extremely limited. But applying similar pricing to diseases affecting millions of people would place enormous financial pressure on healthcare systems.
Smith and Murthy argue that affordability and access must therefore be part of the discussion from the beginning. Even a highly effective gene therapy could create new healthcare inequalities if only a small percentage of patients could obtain it. Researchers and policymakers must consider not just whether these treatments work, but also whether they can be delivered without making existing disparities worse.
Despite these challenges, the possibility of using gene editing to prevent common diseases is becoming increasingly realistic. Researchers are already conducting early studies to investigate whether a single genetic treatment can produce long-lasting reductions in LDL, commonly known as “bad,” cholesterol. LDL cholesterol contributes to the buildup of fatty deposits inside arteries, which can increase the risk of heart attacks and other cardiovascular problems. Lowering LDL over extended periods is an important strategy for reducing cardiovascular risk.
If gene editing can safely produce sustained reductions, it could eventually offer a new approach to protecting cardiovascular health without requiring patients to take medication indefinitely. However, promising early results will not be enough to justify widespread use. Before these therapies become routine options for common conditions, researchers will need convincing evidence that their benefits last, their risks remain acceptably low over many years, and their costs are manageable. Reliable safeguards will also be essential.
For Smith and Murthy, the objective is not to hold back genetic medicine. It is to make sure that a technology with the potential to transform healthcare is introduced carefully and responsibly. As gene therapy moves beyond rare disorders toward conditions affecting millions of people, the central challenge will be ensuring that the promise of lasting protection does not come at the expense of long-term patient safety.
Source: ScienceDaily
